JP2023166395A5 - - Google Patents

Download PDF

Info

Publication number
JP2023166395A5
JP2023166395A5 JP2023130710A JP2023130710A JP2023166395A5 JP 2023166395 A5 JP2023166395 A5 JP 2023166395A5 JP 2023130710 A JP2023130710 A JP 2023130710A JP 2023130710 A JP2023130710 A JP 2023130710A JP 2023166395 A5 JP2023166395 A5 JP 2023166395A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023130710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023166395A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/036368 external-priority patent/WO2017214282A1/en
Application filed filed Critical
Publication of JP2023166395A publication Critical patent/JP2023166395A/ja
Publication of JP2023166395A5 publication Critical patent/JP2023166395A5/ja
Priority to JP2024210957A priority Critical patent/JP2025032192A/ja
Ceased legal-status Critical Current

Links

JP2023130710A 2016-06-08 2023-08-10 抗ｅｇｆｒ抗体薬物コンジュゲート Ceased JP2023166395A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024210957A JP2025032192A (ja) 2016-06-08 2024-12-04 抗ｅｇｆｒ抗体薬物コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662347416P 2016-06-08 2016-06-08
US62/347,416 2016-06-08
PCT/US2017/036368 WO2017214282A1 (en) 2016-06-08 2017-06-07 Anti-egfr antibody drug conjugates
JP2018564215A JP2019521106A (ja) 2016-06-08 2017-06-07 抗ｅｇｆｒ抗体薬物コンジュゲート
JP2021201460A JP2022058351A (ja) 2016-06-08 2021-12-13 抗ｅｇｆｒ抗体薬物コンジュゲート

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021201460A Division JP2022058351A (ja) 2016-06-08 2021-12-13 抗ｅｇｆｒ抗体薬物コンジュゲート

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024210957A Division JP2025032192A (ja) 2016-06-08 2024-12-04 抗ｅｇｆｒ抗体薬物コンジュゲート

Publications (2)

Publication Number Publication Date
JP2023166395A JP2023166395A (ja) 2023-11-21
JP2023166395A5 true JP2023166395A5 (https=) 2024-02-21

Family

ID=59078219

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018564215A Pending JP2019521106A (ja) 2016-06-08 2017-06-07 抗ｅｇｆｒ抗体薬物コンジュゲート
JP2021201460A Pending JP2022058351A (ja) 2016-06-08 2021-12-13 抗ｅｇｆｒ抗体薬物コンジュゲート
JP2023130710A Ceased JP2023166395A (ja) 2016-06-08 2023-08-10 抗ｅｇｆｒ抗体薬物コンジュゲート
JP2024210957A Pending JP2025032192A (ja) 2016-06-08 2024-12-04 抗ｅｇｆｒ抗体薬物コンジュゲート

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018564215A Pending JP2019521106A (ja) 2016-06-08 2017-06-07 抗ｅｇｆｒ抗体薬物コンジュゲート
JP2021201460A Pending JP2022058351A (ja) 2016-06-08 2021-12-13 抗ｅｇｆｒ抗体薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024210957A Pending JP2025032192A (ja) 2016-06-08 2024-12-04 抗ｅｇｆｒ抗体薬物コンジュゲート

Country Status (21)

Country Link
US (3) US20190343961A1 (https=)
EP (2) EP4104865A1 (https=)
JP (4) JP2019521106A (https=)
KR (2) KR20190015526A (https=)
CN (4) CN109563168A (https=)
AU (2) AU2017277517A1 (https=)
BR (1) BR112018075636A2 (https=)
CA (1) CA3027178A1 (https=)
CL (2) CL2018003527A1 (https=)
CO (1) CO2018013497A2 (https=)
CR (1) CR20180614A (https=)
DO (2) DOP2018000272A (https=)
EC (1) ECSP19000157A (https=)
IL (3) IL308054A (https=)
MX (2) MX2018015286A (https=)
PE (1) PE20190512A1 (https=)
PH (2) PH12022553314A1 (https=)
RU (1) RU2018147224A (https=)
SG (2) SG10201914060WA (https=)
TW (3) TW202320860A (https=)
WO (1) WO2017214282A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458479B1 (en) 2016-06-08 2020-11-04 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
BR112018075639A2 (pt) * 2016-06-08 2019-04-09 Abbvie Inc. conjugados de anticorpo fármaco anti-egfr
JP2019521975A (ja) * 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
CN118652192A (zh) * 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
JP7167163B2 (ja) * 2019-05-20 2022-11-08 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 抗体－薬物コンジュゲートの中間体のワンポット合成法による製造プロセス
KR20220024106A (ko) 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
KR20220010527A (ko) * 2019-05-20 2022-01-25 노파르티스 아게 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
KR102787433B1 (ko) 2020-01-30 2025-03-27 성균관대학교산학협력단 면역관문 억제제 및 엑소좀 분비 억제제를 포함하는 항체-약물 접합체 및 이를 포함하는 약학적 조성물
KR20230012592A (ko) 2020-05-19 2023-01-26 르 라보레또레 쎄르비에르 파라-아미노-벤질 링커, 이의 제조 방법 및 컨쥬게이트에서의 이의 용도
AU2021386367A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022231996A1 (en) * 2021-04-26 2022-11-03 The Regents Of The University Of California Combination therapy for treating glioblastoma
EP4359440A1 (en) * 2021-06-22 2024-05-01 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
WO2023208106A1 (zh) * 2022-04-29 2023-11-02 石药集团中奇制药技术（石家庄）有限公司 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物
CN120787162A (zh) 2022-05-20 2025-10-14 诺华股份有限公司 抗肿瘤化合物的抗体-药物缀合物及其使用方法
US20260061065A1 (en) 2022-05-20 2026-03-05 Novartis Ag Antibody drug conjugates
KR20250129814A (ko) 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 항체-약물 접합체 및 이의 용도
AU2024234194A1 (en) 2023-03-10 2025-08-07 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
AR132368A1 (es) 2023-04-18 2025-06-18 Astrazeneca Ab Conjugados que comprenden enlazadores escindibles
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof
KR20250148505A (ko) 2024-04-04 2025-10-14 주식회사 크로스포인트테라퓨틱스 인간 항체 Fc 변이체 포함 항체-약물 접합체 및 그 용도
WO2026037394A1 (zh) * 2024-08-16 2026-02-19 石药集团巨石生物制药有限公司 一种抗体药物偶联物及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1726514A (en) 1926-11-01 1929-08-27 Firm Ferd Liebschner & Sohn Picker for looms
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
AU2003256038A1 (en) 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1737969B2 (en) 2004-04-15 2018-09-12 GlycoFi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP1994000B1 (en) 2006-02-02 2017-08-23 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
EP2217283A2 (en) 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
WO2010138719A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
CN103987711B (zh) * 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN104244718A (zh) 2011-12-05 2014-12-24 伊格尼卡生物治疗公司 抗体-药物缀合物以及相关化合物、组合物和方法
EP2794582A1 (en) 2011-12-23 2014-10-29 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
KR20170093943A (ko) 2014-12-09 2017-08-16 애브비 인코포레이티드 낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체
JP2018506509A (ja) * 2014-12-09 2018-03-08 アッヴィ・インコーポレイテッド 細胞透過性Ｂｃｌ−ｘＬ阻害剤との抗体薬物コンジュゲート
BR112017012342A2 (pt) * 2014-12-09 2018-02-27 Abbvie Inc compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos

Similar Documents

Publication Publication Date Title
JP2023166395A5 (https=)
JP2020039360A5 (https=)
JP2009225799A5 (https=)
JP2009532336A5 (https=)
JP2022031635A5 (https=)
JP2009517057A5 (https=)
JP2004248677A5 (https=)
RU2011110169A (ru) Антитела против ccr2
RU2012119788A (ru) Связывающие il-1 белки
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
JP2021527640A5 (https=)
JP2010511388A5 (https=)
EP2336183A3 (en) Antibodies against CCR5 and uses thereof
EP2426146A3 (en) Anti-human IL-21 monoclonal antibodies
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
RU2009149294A (ru) Антиген-связывающие белки, нацеленные на orf0657n s.aureus
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2010526028A5 (https=)
JP2010536384A5 (https=)
JP2003528052A5 (https=)
RU2003107564A (ru) Антитела к человеческому il-1бета
JP2003525061A5 (https=)
JP2010524435A5 (https=)
RU2003100512A (ru) Антитела к человеческому мср-1
RU2009148597A (ru) Новые показания к применению при лечении антителами против il-1-бета